1 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 26581242 | A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer. | 2016 Mar 1 | 1 |